Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06336928 · ClinicalTrials.gov registry record

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

A clinical trial of Breast Carcinoma, sponsored by University of Southern California.

Recruiting
Registry status
490
Enrollment target
4
Study locations

NCT06336928 is a study of Breast Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 490 participants, below the 766-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06336928, a study of Breast Carcinoma, is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
490 participants
Enrollment target
4
Study locations

Study Summary

This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.

Conditions Studied

Interventions

  • OTHER Non-Interventional Study

Study Locations (4)

California

  • Keck Medicine of USC Koreatown - Los Angeles
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach - Newport Beach

Trial Details

FieldValue
Enrollment Target 490 participants
Start Date 2024-06-07
Est. Completion 2030-06-07

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT06336928

The ClinicalTrials.gov registry entry for NCT06336928 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 766-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (36% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06336928 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06336928 about?

NCT06336928 is a clinical study titled "A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis". This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.

What is the current status of trial NCT06336928?

This trial is currently recruiting. The enrollment target is 490 participants. The study started on 2024-06-07. Estimated completion is 2030-06-07.

What conditions does trial NCT06336928 study?

This clinical trial studies the following conditions: Breast Carcinoma.

What interventions are being tested in trial NCT06336928?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06336928?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06336928 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.